Skip to main content

Advertisement

Table 2 Proteomics studies

From: Diagnostic ‘omics’ for active tuberculosis

Study Sample Data access Country Classes Number Case definition Independent test setc Validation setd Evaluation of accuracy Signature size Protein biomarkers identified
HIV status Prior TB treatmenta TB location Microbiologically provenb TST IGRA
Achkar et al., 2015 [77] Serum Y US TB 37 ≤7d P, EP U    N N Y 10 Y
LTBI 34     + +/–
HC 20     
OD 19      
TB 10 + ≤7d P, EP U    8
LTBI 23 +     + +/–
HC 16 +     
OD 26 +      
Wang et al., 2015 [102] Serum N China TB 122 P U    N N Y 5 Y
Treated 91 2 m     
Cured 59 ≥6 m     
HC 122       
Liu et al., 2015 [72] Serum N China SP-TB 49 P Y    Y N Y 3 N
SN-TB 66 P Y   
HC 80      
Xu et al., 2015 [69] Serum N China TB 40 P Y    N N Y 3 N
HC 40       
OD 80       
Zhang et al., 2014 [103] Plasma N China LTBI 71     + + Y N Y 19 Y
HC 75    
Xu et al., 2014 [92] Serum N China TB 76   P U    N N Y 3 Y
HC 56       
Song et al., 2014 [104] Serum N South Korea TB 26   P U    N N Y 1 Y
HC 31       
Nahid et al., 2014 [105] Serum N Uganda TB 39 ≤5d P Y    N N Y 4 Y
Responder 19 2 m     
Non-responder 20 2 m     
Ou et al., 2013 [106] CSF N China EP-TB 45   EP Y    N N N N/Ae Y
HC 45       
OD 45       
Liu et al., 2013 [70] Serum N China TB 180 P U    Y N Y 4 N
HC 91      
OD 120      
De Groote et al., 2013 [107] Serum N Uganda TB 39 ≤5d P Y    N N N N/Ae Y
Treated 39 2 m     
Zhang et al., 2012 [71] Serum N China TB 129    P Y +   N N Y 3 N
LTBI 36      +  
HC 30       
OD 69       
Sandhu et al., 2012 [73] Plasma N Peru TB 151    P Y    N N Y   N
OD (+LTBI) 53       + 33
OD (-LTBI) 44       57
OD all 110       +/– 98
Liu et al., 2011 [75] Serum N China TB 80   P U    Y N Y 3 N
HC 32      
OD 36      
Deng et al., 2011 [74] Serum N China TB 37 P Y    Y N Y 5 N
EP-TB 81 EP, P U   
HC 40     
OD 35     
Tanaka et al., 2011 [108] Plasma N Japan, Vietnam TB 39 ≤7d P Y    N N N N/Ae Y
HC 63       
Liu et al., 2010 [76] Serum N China SP-TB 51   P Y    Y N Y 9 N
SN-TB 36   P Y    2
HC 55       
OD 13      
Agranoff et al., 2006 [68] Serum N Uganda, The Gambia, Angola, UK TB 197 +/– ≤7d P, EP Y    Y Y Y 4 Y
HC 25 +/–      
OD 168 +/–      
  1. CSF Cerebrospinal fluid, TB Active tuberculosis, LTBI Latent TB infection, HC Healthy controls, OD Other diseases, SP Smear positive, SN Smear negative, EP Extrapulmonary, P Pulmonary; Y yes, N no
  2. anumber of days (d) or months (m) on treatment at time of sampling
  3. bU if unclear whether all TB cases were microbiologically confirmed, e.g. if diagnosis was based on Mtb culture or chest X-ray or TB symptoms, or if microbiologically proven and unproven TB cases were grouped together
  4. cnever involved in training the model (nested, k-fold or leave-one-out cross-validation (without test) are not considered to make use of an independent test set)
  5. dnew, independent set of samples, e.g. from different ethnic background or geographic location
  6. eDifferentially expressed proteins were identified but suitability as biomarkers was not assessed